Despite a roiling political environment on both sides of the Atlantic and what Science called "epic estrangement" between the U.S. president and the scientific community, the biopharma industry produced dazzling clinical breakthroughs in 2017 while U.S. regulators logged record nods, including the first for gene therapy.